

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
11 April 2019 (11.04.2019)



(10) International Publication Number
WO 2019/071073 A1

(51) International Patent Classification:

C07D 401/06 (2006.01) C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2018/054520

(22) International Filing Date:

05 October 2018 (05.10.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/569,177 06 October 2017 (06.10.2017) US

(71) Applicant: **FORMA THERAPEUTICS, INC.** [US/US];
500 Arsenal Street, Suite 100, Watertown, Massachusetts
02472 (US).

(72) Inventors: **CARAVELLA, Justin**; 500 Arsenal Street,
Suite 100, Watertown, Massachusetts 02472 (US). **HAN,
Bingsong**; 500 Arsenal Street, Suite 100, Watertown, Mass-
achusetts 02472 (US). **LIU, Cuixian**; 500 Arsenal Street,
Suite 100, Watertown, Massachusetts 02472 (US). **IOAN-
NIDIS, Stephanos**; 500 Arsenal Street, Suite 100, Wa-
tertown, Massachusetts 02472 (US). **BUCKMELTER,
Alexandre Joseph**; 500 Arsenal Street, Suite 100, Wa-
tertown, Massachusetts 02472 (US). **RICHARD, David
James**; 500 Arsenal Street, Suite 100, Watertown, Massa-
chusetts 02472 (US). **MARTIN, Matthew W.**; 500 Arsenal
Street, Suite 100, Watertown, Massachusetts 02472 (US).
MISCHKE, Steven; 500 Arsenal Street, Suite 100, Water-
town, Massachusetts 02472 (US). **MENTE, Scot**; 500 Ar-
senal Street, Suite 100, Watertown, Massachusetts 02472
(US).

(74) Agent: **REARICK, John P.** et al.; Choate, Hall & Ste-
wart LLP, Two International Place, Boston, Massachusetts
02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30

(57) Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments.



WO 2019/071073 A1